GLUCOSE

Dosage of Glucose depends on the age, weight, clinical condition of the patient. Fluid and acid base balance, serum glucose, serum sodium, and other electrolytes may need to be monitored before and during administration, especially in patients with increased non-osmotic vasopressin release (syndrome of inappropriate antidiuretic hormone secretion, SIADH) and in patients co-medicated with vasopressin agonists due to the risk of hyponatraemia.

Monitoring of serum sodium is particularly important for physiologically hypotonic fluids (in vivo tonicity). 2). Posology Adults and the elderly For the treatment of hypoglycaemia. Administer 100 ml of Glucose 20% (at 400 ml/hour over 15 minutes).

As an energy source and in carbohydrate depletion. Up to 3 Litres per day dependent on the needs of the patient. Paediatric population Only to be used under the supervision of a paediatrician Method of administration Glucose 20% must be administered by the intravenous route; it must not be administered by subcutaneous or intramuscular route.

Except in the emergency treatment of severe hypoglycaemia, Glucose 20% should be administered via a central vein. Glucose 20% is provided in a concentration that is ready for administration.

Very common (≥ 1/10); Common (≥ 1/100 to < 1/10); Uncommon (≥ 1/1,000 to < 1/100); Rare (≥ 1/10,000 to < 1/1,000); Very rare (<1/10,000), Not known (cannot be estimated from the available data) System Organ Class (SOC) Adverse reaction (MedDRA term) Frequency Metabolism and nutrition disorders Hospital acquired hyponatraemia * Not known Hyperglycaemia** Hypokalaemia Hypophosphataemia Hypomagnesaemia Fluid and electrolyte imbalance.

4). ** Hyperglycaemia (possibly indicated by mental confusion or loss of consciousness) and glycosuria may occur as a result of the rate of administration or metabolic insufficiency. If undetected and untreated hyperglycaemia can lead to dehydration, hyperosmolar coma and death.

g. Wernicke’s encephalopathy. Sodium retention, oedema, pulmonary oedema and congestive heart failure may be induced in patients with severe under-nutrition. Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important.

It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

Rapid administration of hypertonic glucose solutions may produce substantial hyperglycaemia and hyperosmolar syndrome; patients should be observed for signs of mental confusion and loss of consciousness, especially those patients with chronic uraemia or carbohydrate intolerance.

Prolonged use in parenteral nutrition may affect insulin production; blood and urine glucose should be monitored. Glucose 20 % intravenous infusion is a hypertonic solution (in vitro, in a container). 2). Depending on the tonicity of the solution, the volume and rate of infusion and depending on a patient’s underlying clinical condition and capability to metabolize glucose, intravenous administration of glucose can cause electrolyte disturbances most importantly hypo- or hyperosmotic hyponatraemia.

g. 5) are at risk of acute hyponatraemia upon infusion of hypotonic fluids. Acute hyponatraemia can lead to acute hyponatraemic encephalopathy (brain oedema) characterized by headache, nausea, seizures, lethargy and vomiting. Patients with brain oedema are at particular risk of severe, irreversible and life-threatening brain injury.

g. meningitis, intracranial bleeding, and cerebral contusion) are at particular risk of the severe and life-threatening brain swelling caused by acute hyponatraemia. 8). Special care should be taken during injection to avoid leakage into the surrounding tissue.

1 and known allergy to corn or corn products • the glucose – galactose malabsorption syndrome • anuria or intraspinal or intracranial haemorrhage, or ischaemic stroke and in patients with delirium tremens if such patients are already dehydrated • hyperglycaemic coma.